300+ investors in your industry, stage, and region Get
Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Singapore
Oceania
LATAM
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Andorra
Colombia
Sudan
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
Paraguay
Canada
South Africa
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Ireland
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database

Xinghua Dingli

VC Fund

Xinghua Dingli is an investment company.

Total investments:
13
Last investment:
Lead investor:
46%

Last updated:

Industries Xinghua Dingli invests in

BiotechnologyMedicalBiopharmaHealth CarePharmaceutical

Stages Xinghua Dingli invests in

SeedSeries ASeries BVenture - Series Unknown

Countries Xinghua Dingli invests in

China

Round sizes

Seed $1.4M–$14M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Seed
$1.4M–$14M

Investment Focus

Industry

  • Biotechnology 7 (54%)
  • Medical 3 (23%)
  • Biopharma 3 (23%)
  • Health Care 3 (23%)
  • Pharmaceutical 3 (23%)
See all 17 industries →

Stage

  • Seed 5 (38%)
  • Series A 3 (23%)
  • Series B 2 (15%)
  • Venture - Series Unknown 1 (8%)

Team

NameTitleInvestmentsLinksEmail
He Jiongling Investment Director
Investment Director Total investments: 1 Find email

Investments

CompanyDescriptionRoundLinks
Kaiwang Data Kaiwang Data
Kaiwang Data is a one-stop shop for data solutions. It focuses on offering complete data labeling solutions for automakers and businesses involved in autonomous driving. $14.8M / Venture - Series Unknown / Aug 04, 2026
Puyuan Bio Puyuan Bio
Primobiology is a developer of live microbial drugs for immune diseases. Seed / May 30, 2024
Puyuan Bio Puyuan Bio
Puyuan Bio engages in the clinical quantitative detection of tumor-specific mRNA in human peripheral blood. Its technology can provide an important clinical diagnosis basis for the presence of hematogenous spread of tumor cells and dynamic monitoring of the disease.The company has a talented team with doctoral tutors, doctors, and masters as themain body, and has 9 national invention patents in related fields. The company was approved by the Ministry of Science and Technology of Science and Technology Small and Medium Enterprises Technology Innovation Fund and passed the acceptance inspection. It is an enterprise settled in the technology transfer plan of Anhui Province and has been included in the Hefei Shuangqian Project. It was supported by the Development and Reform Commission in 2018.The registration application materials of the cytokeratin 19 (CK19) mRNA nucleic acid detection kit (PCR-fluorescent probe method) have been accepted by the State Food and Drug Administration, the on-site inspection of the medical device production quality management standard has been passed, and the approval number will be obtained soon. When it is put into production, it will contribute to public health. $1.4M / Seed / May 30, 2024
Inkedi Microelectronics Inkedi Microelectronics
Inkodi Electronics is a manufacturer of electronic components that specializes in integrated circuit design, chip R&D and design, analog circuit layout design, and electronic component retail. $14.1M / Seed / Dec 28, 2023
Hydrogen Aviation Technology Hydrogen Aviation Technology
Hydrogen Aviation Technology is committed to innovative applications of lightweight hydrogen fuel stacks. Its self-developed hydrogen-powered UAV has reached the international leading level. Series A / Nov 07, 2023
Tianji Jishi Tianji Jishi
Tianji Jishi is a biopharmaceutical company that specializes in researching mitochondria. Series A / Oct 08, 2023
Blue Aspirations Blue Aspirations
Blue Aspirations was formed to use statistics to accelerate the global adoption of renewable energy. Blue Aspirations aims to face the challenges of the next century by leveraging software development and technical knowledge in the renewables business. Series B / Sep 22, 2023
Hangzhou Weiyuan Biotechnology Hangzhou Weiyuan Biotechnology
Hangzhou Weiyuan Biotechnology is a synthetic biology research and development company that specializes in enzyme advancement. Seed / Jun 30, 2023
Nuoyu Pharmaceutical Nuoyu Pharmaceutical
Nuoyu Pharmaceutical is a medical innovative drug producer that emphasizes in nuclear drug research and drug screening. Series A / May 13, 2023
Puyuan Bio Puyuan Bio
Primobiology is a developer of live microbial drugs for immune diseases. $1.5M / Seed / Jan 19, 2023
See all 13 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Singapore
Oceania
LATAM
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Andorra
Colombia
Sudan
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
Paraguay
Canada
South Africa
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Ireland
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Xinghua Dingli invest in?

Xinghua Dingli invests primarily in Biotechnology, Medical and Biopharma startups, most often at Seed and Series A stage. Most of the 13 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is Xinghua Dingli's check size?

Xinghua Dingli typically joins rounds of $1.4M–$14M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Xinghua Dingli participates in.

How do I contact Xinghua Dingli?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Xinghua Dingli?

The team at Xinghua Dingli includes He Jiongling (Investment Director). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Xinghua Dingli Find emails